|
65679643212eaade2e0edd20
|
2018
|
Canada
|
Miscellaneous
|
2018899980a
|
159406-1
|
3
|
Malaysia
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.00462927
|
0
|
0
|
0
|
0.00462927
|
0
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ONCE WEEKLY FOLIC ACID SUPPLEM...ENTATION FOR THE PREVENTION OF NEUTRAL TUBE DEFECTS: A RANDOMIZED CONTROLLED DOSE-FINDING TRIAL
more
|
Once weekly folic acid supplem...entation for the prevention of neutral tube defects: a randomized controlled dose-finding trIal
more
|
|
NTDs
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University of British Columbia
|
|
|
|
65679643212eaade2e0edd21
|
2018
|
Canada
|
Miscellaneous
|
2018899980b
|
159406-1
|
3
|
Malaysia
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.00462927
|
0
|
0
|
0
|
0.00462927
|
0
|
0
|
0.00462927
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ONCE WEEKLY FOLIC ACID SUPPLEM...ENTATION FOR THE PREVENTION OF NEUTRAL TUBE DEFECTS: A RANDOMIZED CONTROLLED DOSE-FINDING TRIAL
more
|
Once weekly folic acid supplem...entation for the prevention of neutral tube defects: a randomized controlled dose-finding trIal
more
|
This research will help to fin...d out the optimal weekly amount of folic acid needed to prevent neglected tropical disease-affected pregnancies in adolescent girls in Malaysia and worldwide.
more
|
NTDs
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University of British Columbia
|
|
|
|
65679643212eaade2e0edd22
|
2018
|
Canada
|
Miscellaneous
|
2018899910a
|
156842-1
|
3
|
Middle East, regional
|
Middle East
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0771545
|
0
|
0
|
0
|
0.0771545
|
0
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
BUILDING AN INTERDISCIPLINARY ...RESEARCH CENTRE ON THE GLOBAL GOVERNANCE OF ANTIMICROBIAL RESISTANCE IN CONFLICTS (G2-ARC)
more
|
Building an Interdisciplinary ...Research Centre on the Global Governance of Antimicrobial Resistance in Conflicts (G2-ARC)
more
|
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université de Sherbrooke
|
|
|
|
65679643212eaade2e0edd23
|
2018
|
Canada
|
Miscellaneous
|
2018899910b
|
156842-1
|
3
|
Middle East, regional
|
Middle East
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0771545
|
0
|
0
|
0
|
0.0771545
|
0
|
0
|
0.0771545
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
BUILDING AN INTERDISCIPLINARY ...RESEARCH CENTRE ON THE GLOBAL GOVERNANCE OF ANTIMICROBIAL RESISTANCE IN CONFLICTS (G2-ARC)
more
|
Building an Interdisciplinary ...Research Centre on the Global Governance of Antimicrobial Resistance in Conflicts (G2-ARC)
more
|
Antimicrobial resistance (AMR)... poses a significant global health challenge to the delivery of healthcare worldwide. Effective antibiotics are essential to cure infections, and for the prevention and treatment of infectious complications in the provision of health services. Many experts agree that if the challenges posed by AMR are not addressed, we will be heading towards a period analogous to the pre-antibiotic era, when infections were synonymous with high mortality rates. To tackle this issue, effective international frameworks and action plans need to be developed. Many global organisations and governments have identified potential solutions with the objective of building governance arrangements. Yet none of these propositions have studied the impacts that conflict settings pose to the development of AMR. Currently more than half of the world's population live in countries with ongoing conflicts. Our research proposal aims to study the links between the emergence of AMR and conflict settings. Our interdisciplinary group will combine approaches from the fields of anthropology, medicine, law and public health to the case study of multidrug-resistant Acinetobacter baumannii (MDRAb). MDRAb, a previously uncommon human pathogen, came to international attention in 2004 following reports of high rates of infections in wounded U.S. soldiers in Iraq. It has since become one of the three most critical pathogens identified by the World Health Organization for the development of new antibiotics. MDRAb remains one of the most common causes of infection among wounded civilians in the many conflicts that persist in the Middle East. In addition to the research we will undertake, we aim to establish at Universite de Sherbrooke an Interdisciplinary Research Centre on the Global Governance of AMR in Conflicts. This centre will be well positioned to conduct inter-sectoral research on the global governance of AMR and to participate in broader international collaborations.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université de Sherbrooke
|
|
|
|
65679643212eaade2e0edd24
|
2018
|
Canada
|
Miscellaneous
|
2018899982a
|
158369-1
|
3
|
Philippines
|
Far East Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.00981967
|
0
|
0
|
0
|
0.00981967
|
0
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PRIORITY SETTING TO ADDRESS TH...E SOCIAL DETERMINANTS OF TUBERCULOSIS INFECTION AND CARE AMONG INCOME POOR HOUSEHOLDS IN THE PHILIPPINES
more
|
Priority setting to address th...e social determinants of tuberculosis infection and care among income poor households in the Philippines
more
|
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University of Waterloo (Ontari...o)
more
|
|
|
|
65679643212eaade2e0edd25
|
2018
|
Canada
|
Miscellaneous
|
2018899982b
|
158369-1
|
3
|
Philippines
|
Far East Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.0154309
|
0
|
0
|
0
|
0.0154309
|
0
|
0
|
0.0154309
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PRIORITY SETTING TO ADDRESS TH...E SOCIAL DETERMINANTS OF TUBERCULOSIS INFECTION AND CARE AMONG INCOME POOR HOUSEHOLDS IN THE PHILIPPINES
more
|
Priority setting to address th...e social determinants of tuberculosis infection and care among income poor households in the Philippines
more
|
The Philippines has one of the... highest burdens of tuberculosis (TB) and multi-drug-resistant tuberculosis (MDR-TB) in the world. Within the Philippines, gendered, socio-economic, and spatial disparities influence who is infected with TB and who is able to access care. For progress to be made on reducing the incidence and burden of TB in the Philippines, there is a need to (1) identify and (2) prioritize the social determinants of TB infection and care. With this grant, we will hold stakeholder consultations with new and existing partners from government, multilateral organizations, civil society, and academia with insights into the gendered, socio-economic, and spatial dimensions and inequities of TB infection and/or care. These consultations will culminate in a two-day in-person meeting with these stakeholders to collectively prioritize the social determinants of TB infection and care, with the intention of setting a collaborative research agenda for future work together. This consultation and meeting process will facilitate the creation of an intersectoral network of partners committed to understanding and addressing the social inequities that underlie TB infection and care in the Philippines.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University of Waterloo (Ontari...o)
more
|
|
|
|
65679644212eaade2e0edd26
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170084110001
|
108411
|
3
|
South America, regional
|
South America
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.010863
|
0
|
0
|
0
|
0.010863
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UNDERSTANDING THE BIOLOGICAL M...ECHANISMS OF ZIKA VIRUS DISEASE
more
|
Understanding the biological m...echanisms of Zika virus disease
more
|
The Zika virus is an emerging ...mosquito-transmitted human pathogen which has affected over 50 countries to date. More than two million infections and 4,000 suspected cases of Zika virus-related birth defects have been recorded in Brazil alone. Unfortunately, there are no antivirals or vaccines currently available.The Zika virus is a unique pathogen with a complex transmission and pathogenic profile. It can be spread through mosquitoes as well as via sexual and mother-to-child transmission. It causes a wide spectrum of disease, ranging from symptom-free infections to mild, self-limiting symptoms, to severe infections requiring hospitalization. Additionally, Zika infection in pregnant women has been linked to microcephaly) and other brain abnormalities in developing fetuses and newborn infants. Zika-affected areas in Brazil have shown an unprecedented rise in birth defects. The complexity and severity of this virus underscores the need for greater research to understand the molecular mechanisms which allow the Zika virus to infect, persist, and spread through infected human cases.This project will use advanced biomolecular, genomics and proteomics techniques to explain the molecular mechanisms by which the Zika virus infects and persists in the human body, how it affects the human reproductive and central nervous system, and how the risk of fetal abnormalities can be better predicted in infected pregnant women. By doing so, the project may identify new opportunities for developing therapies to prevent severe illness in mothers and their infants, and to reduce sexual transmission
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
23000
|
Developing country-based NGO
|
Fundaçao Oswaldo Cruz- FIOCRU...Z
more
|
|
|
|
65679644212eaade2e0edd27
|
2018
|
Canada
|
International Development Rese...arch Centre
more
|
20120069050001
|
106905
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0
|
0.0059068
|
0
|
0
|
0
|
0.0059068
|
|
0
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
POPULATION HEALTH VULNERABILIT...IES TO VECTOR-BORNE DISEASES: INCREASING RESILIENCE UNDER CLIMATE CHANGE CONDITIONS IN AFRICA
more
|
Population Health Vulnerabilit...ies to Vector-borne Diseases: Increasing Resilience under Climate Change Conditions in Africa
more
|
|
|
12182
|
Medical research
|
|
I.2.a. Health, General
|
41143
|
World Health Organisation - co...re voluntary contributions account
more
|
World Health Organization/Orga...nisation mondiale de la santé/Organización Mundial de la Salud
more
|
|
|
|
65679644212eaade2e0edd28
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170085170001
|
108517
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.005033
|
0.005279
|
0
|
0
|
0.005033
|
0.005279
|
0
|
0.005033
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of various strains refers to the use of universal epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
13000
|
Third Country Government (Dele...gated co-operation)
more
|
Institut national de recherche... pour l'agriculture, l'alimentation et l'environnement
more
|
|
|
|
65679644212eaade2e0edd29
|
2019
|
Canada
|
Global Affairs Canada
|
2018200782
|
P001405001
|
3
|
Bangladesh
|
South & Central Asia
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0
|
0.0828937
|
0
|
0
|
0
|
0.0828937
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ICDDR,B - INSTITUTIONAL SUPPOR...T 2018-2022/ICDDR,B - APPUI INSTITUTIONNEL 2018-2022
more
|
icddr,b - Institutional Suppor...t 2018-2022/icddr,b - Appui institutionnel 2018-2022
more
|
This grant represents Canada's... long-term institutional support to icddr,b, formerly known as the International Centre for Diarrhoeal Disease Research, Bangladesh. icddr,b uses these funds, along with other donors' funding to achieve its mandate. icddr,b's mandate is to find low-cost innovative solutions to public health problems facing low- and middle-income countries through scientific research. icddr,b's research and health services contribute to the well-being of women and girls in the area of disease prevention and control (including cholera vaccines administered to Rohingya refugees), sexual and reproductive health and rights, prevention and treatment of malnutrition, prevention of child marriage, and the first population-based research on gender-based violence in Bangladesh. As part of icddr,b's 'Core Donor Group' (Canada, UK, Sweden), Canada's funding is supporting the delivery of free health care, especially for women and children, and strengthening icddr,b's operations through investment in research technologies, human resources development, and initiatives to improve icddr,b's effectiveness, efficiency, and long-term viability. /Cette subvention constitue l'appui institutionnel à long terme du Canada à icddr,b - qui était connu sous le nom Centre international de recherche sur les maladies diarrhéiques, Bangladesh, en anglais : International Centre for Disease Research, Bangladesh. icddr,b utilise ces fonds, ainsi que ceux d'autres donateurs, pour la réalisation de son mandat. Le mandat de icddr,b consiste à trouver des solutions novatrices peu coûteuses aux problèmes de santé publique auxquels sont confrontés les pays à revenu faible ou intermédiaire grâce à la recherche scientifique. La recherche et les services de santé de icddr,b contribuent au bien-être des femmes et des filles dans le domaine de la prévention et du contrôle des maladies (y compris les vaccins cholériques administrés aux réfugiés Rohingya), la santé et les droits sexuels et reproductifs, la prévention de la malnutrition, le mariage des enfants et la première recherche en population sur la violence sexiste au Bangladesh. Faisant partie du groupe de donateurs de base de icddr,b (Canada, Royaume-Uni, Suède), le financement du Canada appuie la prestation gratuite de soins de santé, en particulier pour les femmes et les enfants, et renforce les activités d'icddr,b en investissant dans les technologies de recherche, le développement des ressources humaines, et les initiatives visant à améliorer l'efficacité, l'efficience et la viabilité à long terme d'icddr,b.
more
|
|
13081
|
Personnel development for popu...lation and reproductive health
more
|
3
|
I.3. Population Policies/Progr...ammes & Reproductive Health
more
|
47053
|
International Centre for Diarr...hoeal Disease Research, Bangladesh
more
|
icddr,b
|
|
|
|
65679645212eaade2e0edd2a
|
2019
|
Canada
|
International Development Rese...arch Centre
more
|
20190091522
|
109152
|
1
|
Brazil
|
South America
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.129014
|
0.020028
|
0
|
0
|
0.129014
|
0.020028
|
0
|
0.129014
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICROBIOME MEDIATION OF INTEST...INAL PATHOGEN VIRULENCE THROUGH DIETARY AROMATIC COMPOUND METABOLISM
more
|
Microbiome mediation of intest...inal pathogen virulence through dietary aromatic compound metabolism
more
|
The human intestine routinely ...encounters threatening bacteria that cause disease and death. These bacteria use strategies known as virulence mechanisms to infect and interfere with the normal function of cells, leading to disease. Recent studies have shown that these virulence mechanisms may be affected by signals coming from the very large community of microbes that inhabit the gut (the gut microbiome). Previous studies have shown that small compounds produced by non-harmful bacterial strains from the gut microbiome, collectively known as microbiome-produced small aromatic metabolites (MPSAM), can reduce the virulence of salmonella. The goal of this project is to expand from these findings to investigate how MPSAM and other similar compounds alter virulence mechanisms of harmful bacteria. The project also seeks to determine how the intestinal cells and immune cells respond to MPSAM and identify gut microbiome species that can limit these bacterial infections through the production of these compounds. Results from this research will expand our knowledge on how bacterial metabolites affect infectious agents, with great potential to identify small compounds and bacterial species that will reduce infectious disease. This project was selected for funding through the fifth research competition of the Joint Canada-Israel Health Research Program. This initiative is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation, and the Azrieli Foundation.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governors of The Universit...y of Calgary
more
|
|
|
|
65679646212eaade2e0edd2b
|
2019
|
Canada
|
International Development Rese...arch Centre
more
|
20190091521
|
109152
|
1
|
Caribbean & Central America, r...egional
more
|
Caribbean & Central America
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.125219
|
0.0194389
|
0
|
0
|
0.125219
|
0.0194389
|
0
|
0.125219
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICROBIOME MEDIATION OF INTEST...INAL PATHOGEN VIRULENCE THROUGH DIETARY AROMATIC COMPOUND METABOLISM
more
|
Microbiome mediation of intest...inal pathogen virulence through dietary aromatic compound metabolism
more
|
The human intestine routinely ...encounters threatening bacteria that cause disease and death. These bacteria use strategies known as virulence mechanisms to infect and interfere with the normal function of cells, leading to disease. Recent studies have shown that these virulence mechanisms may be affected by signals coming from the very large community of microbes that inhabit the gut (the gut microbiome). Previous studies have shown that small compounds produced by non-harmful bacterial strains from the gut microbiome, collectively known as microbiome-produced small aromatic metabolites (MPSAM), can reduce the virulence of salmonella. The goal of this project is to expand from these findings to investigate how MPSAM and other similar compounds alter virulence mechanisms of harmful bacteria. The project also seeks to determine how the intestinal cells and immune cells respond to MPSAM and identify gut microbiome species that can limit these bacterial infections through the production of these compounds. Results from this research will expand our knowledge on how bacterial metabolites affect infectious agents, with great potential to identify small compounds and bacterial species that will reduce infectious disease. This project was selected for funding through the fifth research competition of the Joint Canada-Israel Health Research Program. This initiative is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation, and the Azrieli Foundation.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governors of The Universit...y of Calgary
more
|
|
|
|
65679646212eaade2e0edd2c
|
2019
|
Canada
|
International Development Rese...arch Centre
more
|
2016008404
|
108404
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0449172
|
0
|
0
|
0
|
0.0449172
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
EPITOPE FOCUSED IMMUNOGENS AND... RECOMBINANT ANTIBODY THERAPEUTICS FOR THE CONTROL OF TROPICAL DISEASES
more
|
Epitope focused immunogens and... recombinant antibody therapeutics for the control of tropical diseases
more
|
Tropical diseases in humans an...d livestock can cause death and remain a huge economic and social burden in developing countries. Currently, 3.6 billion people are at risk of dengue infection. Endemic in 100 countries, with an estimated 390 million annual infections and approximately 500,000 hospitalizations yearly, dengue fever is a worldwide challenge for public health officials and policymakers. East Coast fever is a tick-borne disease affecting cattle, caused by the protozoan parasite Theileria parva. With a 3–4 week incubation period and 100% mortality rate in exotic cattle, it has a devastating economic impact on pastoralists and smallholder farmers in Africa. Combining cutting-edge immunology and protein engineering methods, this collaborative research project aims to develop affordable antibody-based therapies for dengue patients and improved vaccines for the control of dengue fever and East Coast fever in both humans and animals. The core technologies that will be employed reduce the use of animals in research and are easy and affordable to implement, which make these approaches particularly appealing to research groups based in low- and middle-income countries. In Canada, the project is led by the University of Toronto, in collaboration with Tel Aviv University (Israel), the International Livestock Research Institute (Kenya), the SciGenom Labs (India), and the Albert Einstein College of Medicine (USA). It was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, a partnership between IDRC, the Canadian Institutes for Health Research, the Israel Science Foundation, and the Azrieli Foundation. This seven-year, CA$35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. Projects include a plan for integrating researchers from low- and middle-income countries to establish long-term scientific relationships.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governing Council of the U...niversity of Toronto
more
|
|
|
|
65679646212eaade2e0edd2d
|
2019
|
Canada
|
International Development Rese...arch Centre
more
|
2016008407
|
108407
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.048967
|
0
|
0
|
0
|
0.048967
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MITOCHONDRIAL CONTRIBUTION TO ...INNATE IMMUNE PATHWAYS
more
|
Mitochondrial contribution to ...innate immune pathways
more
|
The ability of cells in the bo...dy to recognize bacteria and viruses is critical to survival. Depending on the type of infection, the cell will activate different pathways that generally lead to two distinct responses; first, the cell will secrete proteins called cytokines that alert neighbouring cells to the infection, particularly cells of the immune system. Second, a series of events are triggered to shut down the replication of the pathogen inside the cell. This direct cellular response to infection is called innate immunity. Over the past few years, researchers have identified a critical role for an intracellular organelle, called mitochondria, in the propagation of these signals. Mitochondria are well known as the energy powerhouse of the cell, however, they can also act as a platform to assemble anti-viral and anti-inflammatory signalling. In addition, mitochondria still retain bacterial signatures, including their own unmethylated DNA, as well as the machinery to translate proteins. It was recently shown that this mitochondrial DNA is released into the cell cytoplasm under certain stress conditions. When this happens, the cellular antiviral responses are initiated, as if the cell was infected with bacteria. In this way, mitochondria play a central role as both a signalling platform to launch the protective response to infection, and as a direct activator of this response when their own DNA is released. This project aims to investigate the role of mitochondria in innate immune responses and to develop a detailed understanding of how mitochondria control innate immune signalling pathways. The project is led in Canada by the Montreal Neurological Institute – McGill University in collaboration with the Weizmann Institute (Israel), Universidad Andres Bello (Chile), and the National Institute of Biological Sciences (China). It was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, which is a partnership between Canada's International Development Research Centre, the Canadian Institutes for Health Research, the Israel Science Foundation and the Azrieli Foundation. This seven-year, $35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. All projects include a plan for integrating researchers from low- and middle-income countries that will establish long-term scientific relationships.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Royal Institution for the ...Advancement of Learning/McGill University
more
|
|
|
|
65679646212eaade2e0edd2e
|
2019
|
Canada
|
International Development Rese...arch Centre
more
|
20170085173
|
108517
|
3
|
Far East Asia, regional
|
Far East Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.023322
|
0
|
0
|
0
|
0.023322
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of 'various strains' refers to the use of 'universal' epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
13000
|
Third Country Government (Dele...gated co-operation)
more
|
Institut national de la recher...che agronomique FR
more
|
|
|
|
65679646212eaade2e0edd2f
|
2019
|
Canada
|
International Development Rese...arch Centre
more
|
20170085174
|
108517
|
3
|
Far East Asia, regional
|
Far East Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0139556
|
0
|
0
|
0
|
0.0139556
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of 'various strains' refers to the use of 'universal' epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université du Québec à Mont...réal
more
|
|
|
|
65679646212eaade2e0edd30
|
2019
|
Canada
|
International Development Rese...arch Centre
more
|
20190091523
|
109152
|
1
|
Middle East, regional
|
Middle East
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.125219
|
0.0194389
|
0
|
0
|
0.125219
|
0.0194389
|
0
|
0.125219
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICROBIOME MEDIATION OF INTEST...INAL PATHOGEN VIRULENCE THROUGH DIETARY AROMATIC COMPOUND METABOLISM
more
|
Microbiome mediation of intest...inal pathogen virulence through dietary aromatic compound metabolism
more
|
The human intestine routinely ...encounters threatening bacteria that cause disease and death. These bacteria use strategies known as virulence mechanisms to infect and interfere with the normal function of cells, leading to disease. Recent studies have shown that these virulence mechanisms may be affected by signals coming from the very large community of microbes that inhabit the gut (the gut microbiome). Previous studies have shown that small compounds produced by non-harmful bacterial strains from the gut microbiome, collectively known as microbiome-produced small aromatic metabolites (MPSAM), can reduce the virulence of salmonella. The goal of this project is to expand from these findings to investigate how MPSAM and other similar compounds alter virulence mechanisms of harmful bacteria. The project also seeks to determine how the intestinal cells and immune cells respond to MPSAM and identify gut microbiome species that can limit these bacterial infections through the production of these compounds. Results from this research will expand our knowledge on how bacterial metabolites affect infectious agents, with great potential to identify small compounds and bacterial species that will reduce infectious disease. This project was selected for funding through the fifth research competition of the Joint Canada-Israel Health Research Program. This initiative is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation, and the Azrieli Foundation.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governors of The Universit...y of Calgary
more
|
|
|
|
65679647212eaade2e0edd31
|
2019
|
Canada
|
International Development Rese...arch Centre
more
|
20170085171
|
108517
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.023322
|
0
|
0
|
0
|
0.023322
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of 'various strains' refers to the use of 'universal' epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
13000
|
Third Country Government (Dele...gated co-operation)
more
|
Institut national de la recher...che agronomique FR
more
|
|
|
|
65679647212eaade2e0edd32
|
2019
|
Canada
|
International Development Rese...arch Centre
more
|
20170085172
|
108517
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0139556
|
0
|
0
|
0
|
0.0139556
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of 'various strains' refers to the use of 'universal' epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université du Québec à Mont...réal
more
|
|
|
|
65679648212eaade2e0edd33
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20190091520003
|
109152
|
3
|
Brazil
|
South America
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.041642
|
0
|
0
|
0
|
0.041642
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICROBIOME MEDIATION OF INTEST...INAL PATHOGEN VIRULENCE THROUGH DIETARY AROMATIC COMPOUND METABOLISM
more
|
Microbiome mediation of intest...inal pathogen virulence through dietary aromatic compound metabolism
more
|
The human intestine routinely ...encounters threatening bacteria that cause disease and death. These bacteria use strategies known as virulence mechanisms to infect and interfere with the normal function of cells, leading to disease. Recent studies have shown that these virulence mechanisms may be affected by signals coming from the very large community of microbes that inhabit the gut (the gut microbiome). Previous studies have shown that small compounds produced by non-harmful bacterial strains from the gut microbiome, collectively known as microbiome-produced small aromatic metabolites (MPSAM), can reduce the virulence of salmonella. The goal of this project is to expand from these findings to investigate how MPSAM and other similar compounds alter virulence mechanisms of harmful bacteria. The project also seeks to determine how the intestinal cells and immune cells respond to MPSAM and identify gut microbiome species that can limit these bacterial infections through the production of these compounds. Results from this research will expand our knowledge on how bacterial metabolites affect infectious agents, with great potential to identify small compounds and bacterial species that will reduce infectious disease. This project was selected for funding through the fifth research competition of the Joint Canada-Israel Health Research Program. This initiative is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation, and the Azrieli Foundation.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governors of The Universit...y of Calgary
more
|
|
|
|
65679648212eaade2e0edd34
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20190091520001
|
109152
|
3
|
Caribbean & Central America, r...egional
more
|
Caribbean & Central America
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.038137
|
0
|
0
|
0
|
0.038137
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICROBIOME MEDIATION OF INTEST...INAL PATHOGEN VIRULENCE THROUGH DIETARY AROMATIC COMPOUND METABOLISM
more
|
Microbiome mediation of intest...inal pathogen virulence through dietary aromatic compound metabolism
more
|
The human intestine routinely ...encounters threatening bacteria that cause disease and death. These bacteria use strategies known as virulence mechanisms to infect and interfere with the normal function of cells, leading to disease. Recent studies have shown that these virulence mechanisms may be affected by signals coming from the very large community of microbes that inhabit the gut (the gut microbiome). Previous studies have shown that small compounds produced by non-harmful bacterial strains from the gut microbiome, collectively known as microbiome-produced small aromatic metabolites (MPSAM), can reduce the virulence of salmonella. The goal of this project is to expand from these findings to investigate how MPSAM and other similar compounds alter virulence mechanisms of harmful bacteria. The project also seeks to determine how the intestinal cells and immune cells respond to MPSAM and identify gut microbiome species that can limit these bacterial infections through the production of these compounds. Results from this research will expand our knowledge on how bacterial metabolites affect infectious agents, with great potential to identify small compounds and bacterial species that will reduce infectious disease. This project was selected for funding through the fifth research competition of the Joint Canada-Israel Health Research Program. This initiative is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation, and the Azrieli Foundation.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governors of The Universit...y of Calgary
more
|
|
|
|
65679649212eaade2e0edd35
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20190091520002
|
109152
|
3
|
Caribbean & Central America, r...egional
more
|
Caribbean & Central America
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.002282
|
0
|
0
|
0
|
0.002282
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICROBIOME MEDIATION OF INTEST...INAL PATHOGEN VIRULENCE THROUGH DIETARY AROMATIC COMPOUND METABOLISM
more
|
Microbiome mediation of intest...inal pathogen virulence through dietary aromatic compound metabolism
more
|
The human intestine routinely ...encounters threatening bacteria that cause disease and death. These bacteria use strategies known as virulence mechanisms to infect and interfere with the normal function of cells, leading to disease. Recent studies have shown that these virulence mechanisms may be affected by signals coming from the very large community of microbes that inhabit the gut (the gut microbiome). Previous studies have shown that small compounds produced by non-harmful bacterial strains from the gut microbiome, collectively known as microbiome-produced small aromatic metabolites (MPSAM), can reduce the virulence of salmonella. The goal of this project is to expand from these findings to investigate how MPSAM and other similar compounds alter virulence mechanisms of harmful bacteria. The project also seeks to determine how the intestinal cells and immune cells respond to MPSAM and identify gut microbiome species that can limit these bacterial infections through the production of these compounds. Results from this research will expand our knowledge on how bacterial metabolites affect infectious agents, with great potential to identify small compounds and bacterial species that will reduce infectious disease. This project was selected for funding through the fifth research competition of the Joint Canada-Israel Health Research Program. This initiative is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation, and the Azrieli Foundation.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governors of The Universit...y of Calgary
more
|
|
|
|
65679649212eaade2e0edd36
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20160084040002
|
108404
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.004451
|
0
|
0
|
0
|
0.004451
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
EPITOPE FOCUSED IMMUNOGENS AND... RECOMBINANT ANTIBODY THERAPEUTICS FOR THE CONTROL OF TROPICAL DISEASES
more
|
Epitope focused immunogens and... recombinant antibody therapeutics for the control of tropical diseases
more
|
Tropical diseases in humans an...d livestock can cause death and remain a huge economic and social burden in developing countries. Currently, 3.6 billion people are at risk of dengue infection. Endemic in 100 countries, with an estimated 390 million annual infections and approximately 500,000 hospitalizations yearly, dengue fever is a worldwide challenge for public health officials and policymakers. East Coast fever is a tick-borne disease affecting cattle, caused by the protozoan parasite Theileria parva. With a 3–4 week incubation period and 100% mortality rate in exotic cattle, it has a devastating economic impact on pastoralists and smallholder farmers in Africa. Combining cutting-edge immunology and protein engineering methods, this collaborative research project aims to develop affordable antibody-based therapies for dengue patients and improved vaccines for the control of dengue fever and East Coast fever in both humans and animals. The core technologies that will be employed reduce the use of animals in research and are easy and affordable to implement, which make these approaches particularly appealing to research groups based in low- and middle-income countries. In Canada, the project is led by the University of Toronto, in collaboration with Tel Aviv University (Israel), the International Livestock Research Institute (Kenya), the SciGenom Labs (India), and the Albert Einstein College of Medicine (USA). It was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, a partnership between IDRC, the Canadian Institutes for Health Research, the Israel Science Foundation, and the Azrieli Foundation. This seven-year, CA$35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. Projects include a plan for integrating researchers from low- and middle-income countries to establish long-term scientific relationships.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governing Council of the U...niversity of Toronto
more
|
|
|
|
65679649212eaade2e0edd37
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20160084070002
|
108407
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.009872
|
0
|
0
|
0
|
0.009872
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MITOCHONDRIAL CONTRIBUTION TO ...INNATE IMMUNE PATHWAYS
more
|
Mitochondrial contribution to ...innate immune pathways
more
|
The ability of cells in the bo...dy to recognize bacteria and viruses is critical to survival. Depending on the type of infection, the cell will activate different pathways that generally lead to two distinct responses, first, the cell will secrete proteins called cytokines that alert neighbouring cells to the infection, particularly cells of the immune system. Second, a series of events are triggered to shut down the replication of the pathogen inside the cell. This direct cellular response to infection is called innate immunity. Over the past few years, researchers have identified a critical role for an intracellular organelle, called mitochondria, in the propagation of these signals. Mitochondria are well known as the energy powerhouse of the cell, however, they can also act as a platform to assemble anti-viral and anti-inflammatory signalling. In addition, mitochondria still retain bacterial signatures, including their own unmethylated DNA, as well as the machinery to translate proteins. It was recently shown that this mitochondrial DNA is released into the cell cytoplasm under certain stress conditions. When this happens, the cellular antiviral responses are initiated, as if the cell was infected with bacteria. In this way, mitochondria play a central role as both a signalling platform to launch the protective response to infection, and as a direct activator of this response when their own DNA is released. This project aims to investigate the role of mitochondria in innate immune responses and to develop a detailed understanding of how mitochondria control innate immune signalling pathways. The project is led in Canada by the Montreal Neurological Institute – McGill University in collaboration with the Weizmann Institute (Israel), Universidad Andres Bello (Chile), and the National Institute of Biological Sciences (China). It was selected and approved for funding through the second research competition of the Joint Canada-Israel Health Research Program, which is a partnership between Canada's International Development Research Centre, the Canadian Institutes for Health Research, the Israel Science Foundation and the Azrieli Foundation. This seven-year, $35M Canadian-Israeli effort draws on the unique scientific strengths of both countries and facilitates networking opportunities with peers from Africa, Asia, and Latin America. All projects include a plan for integrating researchers from low- and middle-income countries that will establish long-term scientific relationships.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Royal Institution for the ...Advancement of Learning/McGill University
more
|
|
|
|
65679649212eaade2e0edd38
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20180087040002
|
108704
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.010177
|
0
|
0
|
0
|
0.010177
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
USING CRISPR/CAS9 GENE EDITING... FOR INCREASED VACCINE YIELDS IN AVIAN CELL LINES
more
|
Using CRISPR/cas9 gene editing... for increased vaccine yields in avian cell lines
more
|
Virus production for vaccines ...is still a challenging issue, particularly with slow-growing viruses such as influenza. Many vaccines are produced in embryonated hen's eggs or continuous avian cell lines. These cells have an inner mechanism, an antiviral immune response that tries to fight the infection and therefore inhibits the replication of viruses. However, when trying to grow viruses for vaccine production, this becomes a bottleneck in the manufacture of numerous vaccines. This project proposes to switch off this normal anti-viral mechanism to allow for more virus production.Type level I interferons are proteins that protect cells from virus infection by switching on specific anti-viral genes. Among these are the interferon-inducible transmembrane (IFITM) genes. These proteins have been shown to inhibit the replication of several highly pathogenic animal and human viruses, including Ebola, influenza, and HIV-1. The implementing agency for this project, the Pirbright Institute, has shown that a reduction in the level of IFITM in chicken cells infected with influenza produce more virus than normal cells. This finding suggests that IFITMs have an important role to play in the control of viral infections and may be valuable in terms of vaccine production.This project aims to generate cells lacking IFITM using gene editing techniques. It is believed that this approach will overcome a barrier in vaccine production, resulting in increased vaccine yields and reduced manufacturing time. This vaccine platform has the potential to reduce costs of production for many existing vaccines, thus enhancing vaccine availability for a wide range of livestock diseases important to smallholders in developing countries.This project is funded through the Livestock Vaccine Innovation Fund, a partnership of the Bill and Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
31182
|
Agricultural research
|
2
|
III.1.a. Agriculture
|
22000
|
Donor country-based NGO
|
The Pirbright Institute
|
|
|
|
65679649212eaade2e0edd39
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20180087040001
|
108704
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.008671
|
0
|
0
|
0
|
0.008671
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
USING CRISPR/CAS9 GENE EDITING... FOR INCREASED VACCINE YIELDS IN AVIAN CELL LINES
more
|
Using CRISPR/cas9 gene editing... for increased vaccine yields in avian cell lines
more
|
Virus production for vaccines ...is still a challenging issue, particularly with slow-growing viruses such as influenza. Many vaccines are produced in embryonated hen's eggs or continuous avian cell lines. These cells have an inner mechanism, an antiviral immune response that tries to fight the infection and therefore inhibits the replication of viruses. However, when trying to grow viruses for vaccine production, this becomes a bottleneck in the manufacture of numerous vaccines. This project proposes to switch off this normal anti-viral mechanism to allow for more virus production.Type level I interferons are proteins that protect cells from virus infection by switching on specific anti-viral genes. Among these are the interferon-inducible transmembrane (IFITM) genes. These proteins have been shown to inhibit the replication of several highly pathogenic animal and human viruses, including Ebola, influenza, and HIV-1. The implementing agency for this project, the Pirbright Institute, has shown that a reduction in the level of IFITM in chicken cells infected with influenza produce more virus than normal cells. This finding suggests that IFITMs have an important role to play in the control of viral infections and may be valuable in terms of vaccine production.This project aims to generate cells lacking IFITM using gene editing techniques. It is believed that this approach will overcome a barrier in vaccine production, resulting in increased vaccine yields and reduced manufacturing time. This vaccine platform has the potential to reduce costs of production for many existing vaccines, thus enhancing vaccine availability for a wide range of livestock diseases important to smallholders in developing countries.This project is funded through the Livestock Vaccine Innovation Fund, a partnership of the Bill and Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
31182
|
Agricultural research
|
2
|
III.1.a. Agriculture
|
22000
|
Donor country-based NGO
|
The Pirbright Institute
|
|
|
|
6567964a212eaade2e0edd3a
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20200092820003
|
109282
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.044058
|
0
|
0
|
0
|
0.044058
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MACHINE LEARNING FOR DIGITAL D...IAGNOSTICS OF ANTIMICROBIAL RESISTANCE
more
|
Machine learning for digital d...iagnostics of antimicrobial resistance
more
|
If action is not taken, antimi...crobial resistance (AMR) will cost $100 trillion and claim 10 million lives annually by 2050. The factors driving AMR extend beyond human healthcare, with implications in veterinary medicine, agriculture, and the environment. New and improved approaches for tackling AMR include better monitoring, rational drug use, different business models to generate antibiotics, innovation at all levels, and most importantly, a global approach. This project assembles a transnational team (Canada, China, Finland, France) to apply new machine learning approaches for faster diagnosis and better monitoring of resistance. The initial focus will be on two major global pathogens that have developed multi-drug resistance: Pseudomonas aeruginosa and Streptococcus pneumoniae. The research team will develop machine learning that can orient treatment selection by assessing the level of resistance, providing a rationale for generating novel antibiotics, and assisting in the surveillance of human and livestock antimicrobial resistance. This is one of five IDRC-funded projects developed through the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), an international collaborative platform that coordinates global funding to support collaborative research and action on antimicrobial resistance. Through the JPIAMR, IDRC has partnered with 18 other donor agencies to fund innovative research projects on diagnostics and surveillance strategies, as well as tools and technologies that can be used to detect and monitor antimicrobial resistance in human, veterinary, and environmental settings, particularly in low- and middle-income countries.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Institute of Microbiology
|
|
|
|
6567964a212eaade2e0edd3b
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20200092820001
|
109282
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.037534
|
0
|
0
|
0
|
0.037534
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MACHINE LEARNING FOR DIGITAL D...IAGNOSTICS OF ANTIMICROBIAL RESISTANCE
more
|
Machine learning for digital d...iagnostics of antimicrobial resistance
more
|
If action is not taken, antimi...crobial resistance (AMR) will cost $100 trillion and claim 10 million lives annually by 2050. The factors driving AMR extend beyond human healthcare, with implications in veterinary medicine, agriculture, and the environment. New and improved approaches for tackling AMR include better monitoring, rational drug use, different business models to generate antibiotics, innovation at all levels, and most importantly, a global approach. This project assembles a transnational team (Canada, China, Finland, France) to apply new machine learning approaches for faster diagnosis and better monitoring of resistance. The initial focus will be on two major global pathogens that have developed multi-drug resistance: Pseudomonas aeruginosa and Streptococcus pneumoniae. The research team will develop machine learning that can orient treatment selection by assessing the level of resistance, providing a rationale for generating novel antibiotics, and assisting in the surveillance of human and livestock antimicrobial resistance. This is one of five IDRC-funded projects developed through the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), an international collaborative platform that coordinates global funding to support collaborative research and action on antimicrobial resistance. Through the JPIAMR, IDRC has partnered with 18 other donor agencies to fund innovative research projects on diagnostics and surveillance strategies, as well as tools and technologies that can be used to detect and monitor antimicrobial resistance in human, veterinary, and environmental settings, particularly in low- and middle-income countries.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Institute of Microbiology
|
|
|
|
6567964a212eaade2e0edd3c
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20200092820004
|
109282
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.169423
|
0.040285
|
0
|
0
|
0.169423
|
0.040285
|
0
|
0.169423
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MACHINE LEARNING FOR DIGITAL D...IAGNOSTICS OF ANTIMICROBIAL RESISTANCE.
more
|
Machine learning for digital d...iagnostics of antimicrobial resistance.
more
|
The discovery of antimicrobial... agents was one of the great triumphs of the 20th century. Unfortunately, antibiotic resistance was part of the process as well. If nothing is done by 2050, antimicrobial resistance (AMR) will cost $100 trillion with 10 million people/year expected to die. Factors driving AMR extend beyond human healthcare with implications in veterinary medicine, agriculture and the environment (the One Health approach). New and improved approaches for tackling AMR include better monitoring, rational drug use, different business model for generating antibiotics, innovation at all levels and most importantly, a global approach. This transnational team grant proposal is tasked to apply new machine learning approaches for modelling AMR for faster diagnosis, better monitoring and prediction of resistance emergence. The initial focus will be on two worldwide important pathogens, Pseudomonas aeruginosa and Streptococcus pneumoniae, that have developed multidrug resistance. Specifically, the research team will develop machine learning implementation that can orient the selection of treatments by assessing the level of resistance, provide rationale for the generation of novel antibiotics, and assist in the surveillance of human and livestock antimicrobial resistance around the globe. To achieve this, scientists have assembled a transnational team (Canada, China, Finland, France) with complementary skills and demonstrated expertise in machine learning applied to genomics, metabolomics and antimicrobial resistance. This multi-country collaboration included China as an LMIC with expertise in the field. Additionally, the use of antimicrobials in China is three times higher than in the Western world and they have access to multiple bacterial isolates that will help advance faster the research. The final product is aimed to be available worldwide, including LMICs. This project is one of five IDRC funded projects which were developed through the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), an international collaborative platform that coordinates global funding to support collaborative research and action on antimicrobial resistance. Through the JPIAMR, IDRC has partnered with 18 other donor agencies to fund innovative research projects on diagnostics and surveillance strategies, tools and technologies that can be used to detect and monitor antimicrobial resistance in human, veterinary animal and environmental settings particularly in LMICs.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Institute of Microbiology
|
|
|
|
6567964a212eaade2e0edd3d
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20200092820002
|
109282
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.144326
|
0.034313
|
0
|
0
|
0.144326
|
0.034313
|
0
|
0.144326
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MACHINE LEARNING FOR DIGITAL D...IAGNOSTICS OF ANTIMICROBIAL RESISTANCE.
more
|
Machine learning for digital d...iagnostics of antimicrobial resistance.
more
|
The discovery of antimicrobial... agents was one of the great triumphs of the 20th century. Unfortunately, antibiotic resistance was part of the process as well. If nothing is done by 2050, antimicrobial resistance (AMR) will cost $100 trillion with 10 million people/year expected to die. Factors driving AMR extend beyond human healthcare with implications in veterinary medicine, agriculture and the environment (the One Health approach). New and improved approaches for tackling AMR include better monitoring, rational drug use, different business model for generating antibiotics, innovation at all levels and most importantly, a global approach. This transnational team grant proposal is tasked to apply new machine learning approaches for modelling AMR for faster diagnosis, better monitoring and prediction of resistance emergence. The initial focus will be on two worldwide important pathogens, Pseudomonas aeruginosa and Streptococcus pneumoniae, that have developed multidrug resistance. Specifically, the research team will develop machine learning implementation that can orient the selection of treatments by assessing the level of resistance, provide rationale for the generation of novel antibiotics, and assist in the surveillance of human and livestock antimicrobial resistance around the globe. To achieve this, scientists have assembled a transnational team (Canada, China, Finland, France) with complementary skills and demonstrated expertise in machine learning applied to genomics, metabolomics and antimicrobial resistance. This multi-country collaboration included China as an LMIC with expertise in the field. Additionally, the use of antimicrobials in China is three times higher than in the Western world and they have access to multiple bacterial isolates that will help advance faster the research. The final product is aimed to be available worldwide, including LMICs. This project is one of five IDRC funded projects which were developed through the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), an international collaborative platform that coordinates global funding to support collaborative research and action on antimicrobial resistance. Through the JPIAMR, IDRC has partnered with 18 other donor agencies to fund innovative research projects on diagnostics and surveillance strategies, tools and technologies that can be used to detect and monitor antimicrobial resistance in human, veterinary animal and environmental settings particularly in LMICs.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Institute of Microbiology
|
|
|
|
6567964a212eaade2e0edd3e
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170085170007
|
108517
|
3
|
Far East Asia, regional
|
Far East Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.017097
|
0.016239
|
0
|
0
|
0.017097
|
0.016239
|
0
|
0.017097
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading. The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of various strains refers to the use of universal epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs. This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France). The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université du Québec à Mont...réal
more
|
|
|
|
6567964a212eaade2e0edd3f
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170085170005
|
108517
|
3
|
Far East Asia, regional
|
Far East Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.011438
|
0.012004
|
0
|
0
|
0.011438
|
0.012004
|
0
|
0.011438
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of various strains refers to the use of universal epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
13000
|
Third Country Government (Dele...gated co-operation)
more
|
Institut national de recherche... pour l'agriculture, l'alimentation et l'environnement
more
|
|
|
|
6567964a212eaade2e0edd40
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170085170008
|
108517
|
3
|
Far East Asia, regional
|
Far East Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.005361
|
0.005092
|
0
|
0
|
0.005361
|
0.005092
|
0
|
0.005361
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading. The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of various strains refers to the use of universal epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs. This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France). The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université du Québec à Mont...réal
more
|
|
|
|
6567964b212eaade2e0edd41
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170085170006
|
108517
|
3
|
Far East Asia, regional
|
Far East Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.003586
|
0.003758
|
0
|
0
|
0.003586
|
0.003758
|
0
|
0.003586
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading.The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of various strains refers to the use of universal epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs.This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France).The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
13000
|
Third Country Government (Dele...gated co-operation)
more
|
Institut national de recherche... pour l'agriculture, l'alimentation et l'environnement
more
|
|
|
|
6567964b212eaade2e0edd42
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20190091520004
|
109152
|
3
|
Middle East, regional
|
Middle East
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.037049
|
0
|
0
|
0
|
0.037049
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICROBIOME MEDIATION OF INTEST...INAL PATHOGEN VIRULENCE THROUGH DIETARY AROMATIC COMPOUND METABOLISM
more
|
Microbiome mediation of intest...inal pathogen virulence through dietary aromatic compound metabolism
more
|
The human intestine routinely ...encounters threatening bacteria that cause disease and death. These bacteria use strategies known as virulence mechanisms to infect and interfere with the normal function of cells, leading to disease. Recent studies have shown that these virulence mechanisms may be affected by signals coming from the very large community of microbes that inhabit the gut (the gut microbiome). Previous studies have shown that small compounds produced by non-harmful bacterial strains from the gut microbiome, collectively known as microbiome-produced small aromatic metabolites (MPSAM), can reduce the virulence of salmonella. The goal of this project is to expand from these findings to investigate how MPSAM and other similar compounds alter virulence mechanisms of harmful bacteria. The project also seeks to determine how the intestinal cells and immune cells respond to MPSAM and identify gut microbiome species that can limit these bacterial infections through the production of these compounds. Results from this research will expand our knowledge on how bacterial metabolites affect infectious agents, with great potential to identify small compounds and bacterial species that will reduce infectious disease. This project was selected for funding through the fifth research competition of the Joint Canada-Israel Health Research Program. This initiative is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation, and the Azrieli Foundation.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governors of The Universit...y of Calgary
more
|
|
|
|
6567964b212eaade2e0edd43
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20190091520005
|
109152
|
3
|
Middle East, regional
|
Middle East
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.00337
|
0
|
0
|
0
|
0.00337
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MICROBIOME MEDIATION OF INTEST...INAL PATHOGEN VIRULENCE THROUGH DIETARY AROMATIC COMPOUND METABOLISM
more
|
Microbiome mediation of intest...inal pathogen virulence through dietary aromatic compound metabolism
more
|
The human intestine routinely ...encounters threatening bacteria that cause disease and death. These bacteria use strategies known as virulence mechanisms to infect and interfere with the normal function of cells, leading to disease. Recent studies have shown that these virulence mechanisms may be affected by signals coming from the very large community of microbes that inhabit the gut (the gut microbiome). Previous studies have shown that small compounds produced by non-harmful bacterial strains from the gut microbiome, collectively known as microbiome-produced small aromatic metabolites (MPSAM), can reduce the virulence of salmonella. The goal of this project is to expand from these findings to investigate how MPSAM and other similar compounds alter virulence mechanisms of harmful bacteria. The project also seeks to determine how the intestinal cells and immune cells respond to MPSAM and identify gut microbiome species that can limit these bacterial infections through the production of these compounds. Results from this research will expand our knowledge on how bacterial metabolites affect infectious agents, with great potential to identify small compounds and bacterial species that will reduce infectious disease. This project was selected for funding through the fifth research competition of the Joint Canada-Israel Health Research Program. This initiative is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation, and the Azrieli Foundation.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
The Governors of The Universit...y of Calgary
more
|
|
|
|
6567964b212eaade2e0edd44
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170084110002
|
108411
|
3
|
South America, regional
|
South America
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.000649
|
0
|
0
|
0
|
0.000649
|
0
|
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
UNDERSTANDING THE BIOLOGICAL M...ECHANISMS OF ZIKA VIRUS DISEASE
more
|
Understanding the biological m...echanisms of Zika virus disease
more
|
The Zika virus is an emerging ...mosquito-transmitted human pathogen which has affected over 50 countries to date. More than two million infections and 4,000 suspected cases of Zika virus-related birth defects have been recorded in Brazil alone. Unfortunately, there are no antivirals or vaccines currently available.The Zika virus is a unique pathogen with a complex transmission and pathogenic profile. It can be spread through mosquitoes as well as via sexual and mother-to-child transmission. It causes a wide spectrum of disease, ranging from symptom-free infections to mild, self-limiting symptoms, to severe infections requiring hospitalization. Additionally, Zika infection in pregnant women has been linked to microcephaly) and other brain abnormalities in developing fetuses and newborn infants. Zika-affected areas in Brazil have shown an unprecedented rise in birth defects. The complexity and severity of this virus underscores the need for greater research to understand the molecular mechanisms which allow the Zika virus to infect, persist, and spread through infected human cases.This project will use advanced biomolecular, genomics and proteomics techniques to explain the molecular mechanisms by which the Zika virus infects and persists in the human body, how it affects the human reproductive and central nervous system, and how the risk of fetal abnormalities can be better predicted in infected pregnant women. By doing so, the project may identify new opportunities for developing therapies to prevent severe illness in mothers and their infants, and to reduce sexual transmission
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
23000
|
Developing country-based NGO
|
Fundaçao Oswaldo Cruz- FIOCRU...Z
more
|
|
|
|
6567964b212eaade2e0edd45
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170085170004
|
108517
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.014934
|
0.014189
|
0
|
0
|
0.014934
|
0.014189
|
0
|
0.014934
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading. The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of various strains refers to the use of universal epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs. This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France). The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université du Québec à Mont...réal
more
|
|
|
|
6567964c212eaade2e0edd46
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20170085170003
|
108517
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.007523
|
0.007143
|
0
|
0
|
0.007523
|
0.007143
|
0
|
0.007523
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NANOSTRUCTURES FOR THE DEVELOP...MENT OF VACCINES AGAINST AVIAN INFLUENZA VIRUS
more
|
Nanostructures for the develop...ment of vaccines against avian influenza virus
more
|
The influenza virus causes upp...er respiratory tract infections in humans, avian species, and a variety of mammals. The avian influenza virus is a type A virus that is highly mutable. Traditional vaccine strategies against the influenza A virus are susceptible to the emergence of epidemic strains that are beyond vaccination coverage. In addition, there is no vaccine strategy applied to farmed birds affected by the influenza A virus, therefore the emergence of a flu epidemic results in the destruction of livestock to prevent the virus from spreading. The long-term objective of this research project is to develop a new generation vaccine that is inexpensive, easy to administer, and has a broad spectrum to fight the various strains of avian influenza virus. The concept of various strains refers to the use of universal epitope antigens conserved in various strains of avian influenza virus to provide cross-protection. Thus, two highly conserved viral epitopes are targeted. State-of-the-art technologies developed in two laboratories will be combined: nanotechnology and a new adjuvant. These approaches will allow simple production of nanoparticles that do not require any special containment, as opposed to traditional vaccines produced in embryonated eggs. This project is a collaboration between the Université du Québec à Montréal and the National Institute for Agricultural Research (France). The Livestock Vaccine Innovation Fund is a partnership of the Bill & Melinda Gates Foundation, Global Affairs Canada, and IDRC. It represents a joint investment of CA$57 million over five years to support the development, production, and commercialization of innovative vaccines against priority livestock diseases in sub-Saharan Africa, South Asia, and Southeast Asia.
more
|
|
12182
|
Medical research
|
3
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Université du Québec à Mont...réal
more
|
|
|
|
6567964c212eaade2e0edd47
|
2020
|
Canada
|
International Development Rese...arch Centre
more
|
20200095510001
|
109551
|
3
|
Tanzania
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.101118
|
0.096063
|
0
|
0
|
0.101118
|
0.096063
|
0
|
0.101118
|
|
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ASSESSING THE IMPACT OF COVID-...19 RESPONSE ON MALARIA CONTROL AND MALARIA BURDEN IN RURAL TANZANIA
more
|
Assessing the impact of COVID-...19 response on malaria control and malaria burden in rural Tanzania
more
|
The rapid global emergence and... spread of COVID-19 is having extensive effects on the health of populations and health systems worldwide and is threatening fragile health systems in many resource-poor countries. When responding to the COVID-19 pandemic, it is critical to ensure that efforts to control other endemic diseases, such as malaria, are not ignored. Between 2000 and 2015, the massive scale-up of malaria vector control interventions, including long-lasting insecticidal nets, and effective treatment of clinical malaria cases, led to a 50% reduction in malaria cases and deaths in sub-Saharan Africa. There are concerns that tackling COVID-19 will disrupt malaria control efforts, leading to a resurgence in malaria and undermining progress to date. This project investigates the social and public health response to COVID-19 in Tanzania and assesses the impacts of the pandemic on malaria prevention and control at the community and health system levels. The team will identify gaps in the delivery and uptake of malaria interventions in the context of COVID-19. Real-time data on individual behaviours and the effects on health systems will inform locally adapted malaria control strategies. This project was selected for funding through the COVID-19 May 2020 Rapid Research Funding Opportunity, coordinated by the Canadian Institutes of Health Research in partnership with IDRC and other funders.
more
|
|
12262
|
Malaria control
|
3
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University of Ottawa/Universit...é d'Ottawa
more
|
|
COVID-19
|
|
6567964c212eaade2e0edd48
|
2020
|
EU Institutions
|
European Commission
|
2013000492002
|
SCR.CTR.342812
|
3
|
India
|
South & Central Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.016387
|
0
|
0
|
0
|
0.016387
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
EU-INDIA RESEARCH AND INNOVATI...ON PARTNERSHIP ON VACCINE DEVELOPMENT FOR HOOKWORM AND OTHER NEGLECTED TROPICAL DISEASES
more
|
EU-India research and innovati...on partnership on vaccine development for hookworm and other Neglected Tropical Diseases
more
|
The project wil create partner...ships between Indian vaccine manufacturers and the european based vaccine developers The project initially is targeted towards the establishment of long-term partnerships for low-cost manufacture of a vaccine for hookworm and in the later stages will broaden to the development of other vaccines against NTDs
more
|
0
|
12220
|
Basic health care
|
|
I.2.b. Basic Health
|
47053
|
International Centre for Diarr...hoeal Disease Research, Bangladesh
more
|
Centre for Health and Populati...on Research
more
|
|
|
|
6567964c212eaade2e0edd49
|
2017
|
EU Institutions
|
European Development Fund
|
2006100167037
|
AID.CTR.372529
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0143163
|
0
|
0
|
0
|
0.0143163
|
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
FINANCIAL AUDIT OF 'ONE HEALTH... NATIONAL NETWORKS FOR ENHANCED RESEARCH IN INFECTIOUS DISEASES' (FED/2009/217-075)
more
|
Financial audit of 'One health... national networks for enhanced research in infectious diseases' (FED/2009/217-075)
more
|
|
|
43082
|
Research/scientific institutio...ns
more
|
|
IV.2. Other Multisector
|
60000
|
Private sector institution
|
Private sector institution
|
|
|
|
6567964d212eaade2e0edd4a
|
2018
|
EU Institutions
|
European Commission
|
2012000475003
|
SCR.CTR.374522
|
3
|
South America, regional
|
South America
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0198336
|
0
|
0
|
0
|
0.0396672
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
50
|
DESARROLLO Y VALIDACIÓN DE PR...UEBAS DIAGNÓSTICAS E INMUNÓGENOS PARA EL CONTROL DE LAS MICOBACTERIAS QUE AFECTAN HUMANOS Y CERDOS.
more
|
Desarrollo y validación de pr...uebas diagnósticas e inmunógenos para el control de las micobacterias que afectan humanos y cerdos.
more
|
El desarrollo y evaluación de... métodos de diagnóstico e inmunógenos innovativos y/o económicamente más eficientes para la detección de infecciones causadas por micobacterias zoonóticas en los rodeos porcinos del MERCOSUR
more
|
|
31195
|
Livestock/veterinary services
|
|
III.1.a. Agriculture
|
12000
|
Recipient Government
|
Recipient Government
|
|
|
|
6567964d212eaade2e0edd4b
|
2019
|
EU Institutions
|
European Commission
|
2018000918016
|
SI2.816509
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.55951
|
0
|
0
|
0
|
0.55951
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
E+-KA2-EA-INTERNATIONAL HIGHER... EDUCATION CAPACITY BUILDING (CALL 2019)-A4
more
|
E+-KA2-EA-International Higher... Education Capacity Building (Call 2019)-A4
more
|
Empowering universities¿ Lear...ning and rEsearch caPacities in the one Health Approach for the maNagement of animals at the wildlife, livestock and human interface in souTh africa
more
|
|
11420
|
Higher education
|
|
I.1.d. Post-Secondary Educatio...n
more
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
6567964d212eaade2e0edd4c
|
2019
|
Finland
|
Ministry of Foreign Affairs
|
2011110132
|
76908901
|
3
|
Viet Nam
|
Far East Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.0376934
|
0
|
0
|
0
|
0.0376934
|
0
|
0
|
0
|
0
|
Classified as not health-speci...fic activity
more
|
|
100
|
COMMUNITY-CENTERED INTERVENTIO...N TO INCREASE THE ACCESS TO HIGH QUALITY WATER SUPPLIES AMONG ETHNIC MINORITY GROUPS IN LAO CAI
more
|
Community-centered interventio...n to increase the access to high quality water supplies among ethnic minority groups in Lao Cai
more
|
Phase 1 the ?hand washing with... soap? (HWWS) project was successful in increasing hygienic practices and reducing health-related problems. However during this project it was noticed that a lack of clean water during the dry season was a big problem. To ensure the sustainability and and enhance the results of the HWWS project a continuation project is needed concentrating on water access and quality.The continuation project will take 3 years in which the intervention activities (building water supply system and monitoring water quality) will be rolled-out to two communes of Lao Cai city. During the roll-out process the local authorities will gradually be given the responsibility in project management supervision of field work and field staffs as well as the implementation of interventions activities. It is hoped that by the end of the project all of the local stakeholders can manage operate and monitor the quality of water resources by themselves (without financial support from the project) and after the project finishes they can based on their own funding or other external funding implement similar activities to expand interventions at a larger scale (whole province all people of different groups) and therefore can sustain the outcomes of this project.The direct beneficiaries of this continuation project are family members of the poor households in ethnic minority communities of highland villages including: heads of households (the elderly) father mothers and children who have difficulty to access clean water.During end-line workshop different project stakeholders will be invited to attend the workshop and to share lessons learned and results with CERETAD-Health. WaterFinns will use the results and experience gained in this project in its future projects.
more
|
WASH
|
14081
|
Education and training in wate...r supply and sanitation
more
|
|
I.4. Water Supply & Sanitation
|
22000
|
Donor country-based NGO
|
WaterFinns ry
|
|
|
|
6567964e212eaade2e0edd4d
|
2014
|
France
|
MEN
|
2014170289
|
|
8
|
Algeria
|
North of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.0132679
|
0.0132679
|
0
|
0
|
0.0132679
|
0.0132679
|
0
|
0.0132679
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RECH : SÉCURITÉ ALIMENTAIRE,... SANITAIRE, ENVIRON. ET RISQUES NATURELS
more
|
RECH : Sécurité alimentaire,... sanitaire, environ. et risques naturels
more
|
Maladies infectieuses et tropi...cales émergentes (identification moléculaire de pathogènes émergents/étude insectes vecteurs/rech thérapeutique)
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Gouvernement du donneur
|
|
|
|
6567964e212eaade2e0edd4e
|
2014
|
France
|
MEN
|
2014170651
|
|
8
|
Benin
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.620937
|
0.620937
|
0
|
0
|
0.620937
|
0.620937
|
0
|
0.620937
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RECH : SÉCURITÉ ALIMENTAIRE,... SANITAIRE, ENVIRON. ET RISQUES NATURELS
more
|
RECH : Sécurité alimentaire,... sanitaire, environ. et risques naturels
more
|
Maladies Infectieuses et Vecte...urs : Ecologie, Génétique, Evolution et Contrôle
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Gouvernement du donneur
|
|
|
|
6567964e212eaade2e0edd4f
|
2014
|
France
|
MEN
|
2014170653
|
|
8
|
Benin
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.0132679
|
0.0132679
|
0
|
0
|
0.0132679
|
0.0132679
|
0
|
0.0132679
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RECH : SÉCURITÉ ALIMENTAIRE,... SANITAIRE, ENVIRON. ET RISQUES NATURELS
more
|
RECH : Sécurité alimentaire,... sanitaire, environ. et risques naturels
more
|
Maladies Infectieuses et Vecte...urs : Ecologie, Génétique, Evolution et Contrôle
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Gouvernement du donneur
|
|
|
|
6567964e212eaade2e0edd50
|
2014
|
France
|
MEN
|
2014170650
|
|
8
|
Benin
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.00796073
|
0.00796073
|
0
|
0
|
0.00796073
|
0.00796073
|
0
|
0.00796073
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RECH : SÉCURITÉ ALIMENTAIRE,... SANITAIRE, ENVIRON. ET RISQUES NATURELS
more
|
RECH : Sécurité alimentaire,... sanitaire, environ. et risques naturels
more
|
Maladies Infectieuses et Vecte...urs : Ecologie, Génétique, Evolution et Contrôle
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Gouvernement du donneur
|
|
|
|
6567964e212eaade2e0edd51
|
2014
|
France
|
MEN
|
2014170652
|
|
8
|
Benin
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0.00398036
|
0.00398036
|
0
|
0
|
0.00398036
|
0.00398036
|
0
|
0.00398036
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
RECH : SÉCURITÉ ALIMENTAIRE,... SANITAIRE, ENVIRON. ET RISQUES NATURELS
more
|
RECH : Sécurité alimentaire,... sanitaire, environ. et risques naturels
more
|
Maladies Infectieuses et Vecte...urs : Ecologie, Génétique, Evolution et Contrôle
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Gouvernement du donneur
|
|
|
